Cambrian Bio

Cambrian is developing a suite of new medicines that protect people from age-related chronic diseases by increasing healthspan and lifespan through treatment and prevention. Cambrian has a hypothesis-driven approach and an industry-leading portfolio of drug candidates. 

In March 2023, Cambrian announced the launch of Amplifier Therapeutics, a new pipeline company that will focus on the development of ATX-304, a pan-AMPK activator. AMPK is a key energy sensor activated upon increased energy demand, such as exercise and fasting, and is involved in whole-body energy regulation. AMPK activators have broad therapeutic potential in metabolic conditions, cardiovascular diseases, kidney diseases, and cancer.